- List
- By Topic
- On Map
- Search Details

dendritic vaccine | Recruiting, Not yet recruiting, Available Studies | glioma
Need help? See RSS Feeds
Choose a feed type:

dendritic vaccine | Recruiting, Not yet recruiting, Available Studies | glioma (14 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT01567202 | Recruiting | Study of DC Vaccination Against Glioblastoma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
100 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT01567202 | DC81001115 | March 2012 | December 1, 2019 | February 1, 2020 | March 30, 2012 | February 1, 2019 |
|
|||
2 | NCT02465268 | Recruiting | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme |
|
|
Interventional |
Phase 2 |
|
Other / NIH |
|
|
150 | All | 18 Years and older (Adult, Older Adult) | NCT02465268 | IRB201400697-N R01CA175517 OCR14127 |
ATTAC-II | August 2016 | June 2023 | June 2024 | June 8, 2015 | January 24, 2019 |
|
||
3 | NCT03334305 | Recruiting | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
8 | All | 3 Years to 21 Years (Child, Adult) | NCT03334305 | IRB201701867-N R01CA195563 OCR15852 |
ACTION | May 16, 2018 | May 2022 | May 2026 | November 7, 2017 | December 28, 2018 |
|
||
4 | NCT03395587 | Recruiting | Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
136 | All | 18 Years and older (Adult, Older Adult) | NCT03395587 | GlioVax | GlioVax | March 6, 2018 | September 6, 2022 | June 6, 2023 | January 10, 2018 | January 9, 2019 |
|
||
5 | NCT02649582 | Recruiting | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT02649582 | CCRG14-001 | ADDIT-GLIO | December 2015 | December 2020 | December 2022 | January 7, 2016 | May 24, 2018 |
|
||
6 | NCT03360708 | Not yet recruiting | Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma |
|
|
Interventional |
Early Phase 1 |
|
Other / NIH |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT03360708 | MC1772 NCI-2017-02159 P30CA015083 |
March 30, 2019 | December 1, 2022 | December 1, 2022 | December 4, 2017 | February 19, 2019 |
|
|||
7 | NCT03014804 | Not yet recruiting | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma |
|
|
Interventional |
Phase 2 |
|
Other / NIH / Industry |
|
|
30 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03014804 | 16-001706 NCI-2016-01587 P30CA016042 |
January 1, 2019 | January 1, 2020 | January 1, 2022 | January 9, 2017 | October 24, 2018 |
|
|||
8 | NCT03548571 | Recruiting | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
60 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03548571 | DEN-STEM | DEN-STEM | April 26, 2018 | May 1, 2020 | May 1, 2023 | June 7, 2018 | June 7, 2018 |
|
||
9 | NCT03688178 | Not yet recruiting | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
112 | All | 18 Years and older (Adult, Older Adult) | NCT03688178 | Pro00082570 | DERIVe | March 2019 | March 1, 2025 | March 1, 2025 | September 28, 2018 | January 25, 2019 |
|
||
10 | NCT02709616 | Recruiting | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
20 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02709616 | Ag-mRNA-DC-999brain | PERCELLVAC | March 2016 | March 2018 | June 2019 | March 16, 2016 | June 20, 2016 |
|
||
11 | NCT03400917 | Recruiting | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
55 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03400917 | CL-GBM-P01 | June 20, 2018 | October 2020 | June 2023 | January 17, 2018 | January 7, 2019 |
|
|||
12 | NCT01326104 | Recruiting | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / U.S. Fed |
|
|
35 | All | up to 30 Years (Child, Adult) | NCT01326104 | IRB201500502 W81XWH-10-1-0089 CDMRP-PRO93877 OCR13166 |
Re-MATCH | April 2010 | March 2019 | March 2020 | March 30, 2011 | December 28, 2018 |
|
||
13 | NCT02146066 | Available | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
Expanded Access |
|
Industry | All | 18 Years to 70 Years (Adult, Older Adult) | NCT02146066 | 0202EA | DCVax-L EAP | May 23, 2014 | February 26, 2016 |
|
|||||||||
14 | NCT03392545 | Recruiting | Combination of Immunization and Radiotherapy for Recurrent GBM (InSituVac1) |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
30 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03392545 | B0011 | InSituVac1 | April 1, 2018 | April 1, 2020 | June 1, 2020 | January 8, 2018 | October 2, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.